Modulating toll-like receptor signaling as a novel antiinfective approach

Drug News and Perspectives

Volumn 18, Issue 3, 2005, Pages 179-184

  Mbow, M Lamine ^a   Sarisky, Robert T ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMIQUIMOD; INTERFERON; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ARTICLE; CELL MATURATION; CONDYLOMA; DENDRITIC CELL; DIMERIZATION; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; INFECTION; MACROPHAGE; PATHOGENESIS; SIGNAL TRANSDUCTION; VIRUS INFECTION; WART VIRUS;

ANTI-INFECTIVE AGENTS; DIMERIZATION; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 18944407955     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.3.892763     Document Type: Article

References (57)

1. Smith, R. and Coast, J. Antimicrobial resistance: A global response. Bull World Health Organ 2002, 80: 126-33.
2. Kortoyiannis, D. and Lewis, R. Antifungal drug resistance of pathogenic fungi. Lancet 2002, 359: 1135-44.
3. Sefton, A. Mechanisms of antimicrobial resistance: Their clinical relevance in the new millennium. Drugs 2002, 62: 557-66.
4. Gopal, R.G. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998, 55: 323-30.
5. Staphylococcus aureus resistant to vancomycin - United States 2002. MMWR Morb Mortal Wkly Rep 2002, 51: 565-7.
6. McKeegan, K.S., Borges-Walmsley, M.I. and Walmsley, A.R. Microbial and viral drug resistance mechanisms. Trends Microbiol 2002, 10: S8-14.
7. Griffiths, P.D. Resistance in viruses other than HIV. Int J Inf Dis 2002, 6: S32-7.
8. Means, T.K., Golenbock, D.T. and Fenton, M.J. The biology of Toll-like receptors. Cytokine Growth Factor Rev 2000, 11: 219-32.
9. Janeway, C.A., Jr. and Medzhitov, R. Innate immune recognition. Annu Rev Immunol 2002, 20: 197-216.
10. Medzhitov, R. and Janeway, C.A., Jr. Innate immune recognition: Mechanisms and pathways. Immunol Rev 2000, 173: 89-97.
11. Medzhitov, R., Preston-Hurlburt, P. and Janeway, C.A., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388: 394-7.
12. Akira, S., Takeda, K. and Kaisho, T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2: 675-80.
13. Takeda, K., Kaisho, T. and Akira, S. Toll-like receptors. Ann Rev Immunol 2003, 21: 335-76.
14. Lien, E., Sellati, T.J., Yoshimura, A. et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999, 274: 33419-25.
15. Lien, E., Means, T.K., Heine, H. et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000, 105: 497-504.
16. Medzhitov, R.P., Preston-Hurlburt, P., Kopp, E. et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998, 2: 253-8.
17. Muzio, M., Natoli, G., Saccani, S. et al. The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6(TRAF6). J Exp Med 1998, 187: 2097-101.
18. Zhang, F.X., Kirschning, C.J., Mancinelli, R. et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999, 274: 7611-4.
19. Barton, G.M. and Medzhitov, R. Toll-like receptor signaling pathways. Science 2003, 300: 1524-5.
20. Akira, S. and Takeda, K. Toll-like receptor signaling. Nat Rev Immunol 2004, 4: 499-511.
21. Ozinsky, A., Underhill, D.M., Fontenot, J.D. et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000, 97: 13766-71.
22. Wyllie, D.H., Kiss-Toth, E., Visintin, A. et al. Evidence for an accessory protein function for toll-like receptor 1 in anti-bacterial responses. J Immunol 2000, 165: 7125-32.
23. Hajjar, A.M., O'Mahony, D.S., Ozinsky, A. et al. Cutting edge: Functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001, 166: 15-9.
24. Imler, J.L. and Hoffmann, J.A. Toll receptors in innate immunity. Trends Cell Biol 2001, 11: 304-11.
25. Takeuchi, O., Kawai, T., Muhlradt, P.F. et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001, 13: 933-40.
26. Takeuchi, O., Sato, S., Horiuchi, T. et al. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002, 169: 10-4.
27. Alexopoulou, L., Thomas, V., Schnare, M. et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002, 8: 878-84.
28. Latz, E., Visintin, A., Lien, E. et al. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 2002, 277: 47834-43.
29. Zhang, H., Tay, P.N., Cao, W. et al. Integrin-nucleated Toll-like receptor (TLR) dimerization reveals subcellular targeting of TLRs and distinct mechanisms of TLR4 activation and signaling. FEBS Lett 2003, 532: 171-6.
30. Tapping, R.I. and Tobias, P.S. Mycobacterial lipoarabinomannan mediates physical interactions between TLR1 and TLR2 to induce signaling. J Endotoxin Res 2003, 9: 264-8.
31. Sandor, F., Latz, E., Re, F. et al. Importance of extra- and intracellular domains of TLR1 and TLR2 in NFêB signaling. J Cell Biol 2003, 162: 1099-110.
32. Medzhitov, R. and Janeway, C.A., Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296: 298-300.
33. Kobayashi, K., Hernandez, L.D., Galan, J.E. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110: 191-202.
34. Boone, D.L., Turer, E.E., Lee, E.G. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004, 5: 1052-60.
35. O'Reilly, S.M. and Moynagh, P.N. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun 2003, 303: 586-93.
36. Pasare, C. and Medzhitov, R. Toll-like receptors: Balancing host resistance with immune tolerance. Curr Opin Immunol 2003, 15: 677-82.
37. Picard, C., Puel, A., Bonnet, M. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299: 2076-9.
38. Tomai, M.A., Gibson, S.J., Imbertson, L.M. et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995, 28: 253-64.
39. Jurk, M., Heil, F., Vollmer, J. et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 6: 499.
40. Vasilakos, J.P., Smith, R.M, Gibson, S.J. et al. Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN. Cell Immunol 2000, 204: 64-74.
41. Hemmi, H., Kaisho, T., Takeuchi, O. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3: 196-200.
42. Ozinsky, A., Smith, K.D., Hume, D. et al. Co-operative induction of pro-inflammatory signaling by Toll-like receptors. J Endotoxin Res 2000, 6: 393-6.
43. Brawand, P., Fitzpatrick, D.R., Greenfield, B. W. et al. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol 2002, 169: 6711-9.
44. Edwards, A.D., Diebold, S.S., Slack, E.M. et al. Toll-like receptor expression in murine DC subsets: Lack of TLR7 expression by CDS alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003, 33: 827-33.
45. Hochrein, H., Schlatter, B., O'Keeffe, M. et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci USA 2003, 101: 11416-21.
46. Hochrein, H., O'Keeffe, M. and Wagner, H. Human and mouse plasmacytoid dendritic cells. Hum Immunol 2002, 63: 1103-10.
47. Leifer, C.A., Kennedy, M.N., Mazzoni, A. et al. TLR9 is localized in the endoplasmic reticulum prior to Stimulation. J Immunol 2004, 173: 1179-83.
48. Heikenwalder, M., Polymenidou, M., Junt, T. et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10: 187-92.
49. Hurley, J.C. Antibiotic-induced release of endotoxin: A reappraisal. Clin Infect Dis 1992, 15: 840-54.
50. Simon, D.M., Koenig, G. and Trenholme, G.M. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic killed Escherichia coli. J Infect Dis 1991, 164: 800-2.
51. Holzheimer, R.G. The significance of endotoxin release in experimental and clinical sepsis in surgical patients: Evidence for antibiotic-induced endotoxin release? Infect 1998, 26: 77-84.
52. Gogos, C.A., Skoutelis, A., Lekkou, A. et al. Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 2004, 48: 2793-8.
53. Chen, Y., Lenert, P., Weeratna, R. et al. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther 2001, 13: 1024-32.
54. Meng, G., Rutz, M., Schiemann, M. et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004, 113: 1473-81.
55. Schimke, J., Mathison, J., Morgiewicz, J. et al. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998, 95: 13875-80.
56. Bochud, P.Y. and Calandra, T. Pathogenesis of sepsis: New concepts and implications for future treatment. Br Med J 2003, 326: 262-6.
57. Sweet, M.J., Campbell, C.C., Sester, D.P. et al. Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J Immunol 2002, 168: 392-9.